Malarial Dihydrofolate Reductase as Drug Target
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
The | The | ||
<scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Quadruple_mutant/2'>quadruple mutant</scene> of PfDHFR has four | <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Quadruple_mutant/2'>quadruple mutant</scene> of PfDHFR has four | ||
| - | <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Mutated_codons/2'>point mutations</scene>: N51I, C59R, S108N, and I164L.<ref> | + | <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Mutated_codons/2'>point mutations</scene>: N51I, C59R, S108N, and I164L.<ref>Huang F, Tang L, Yang H, Zhou S, Liu H, Li J, Guo S. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J. 2012 Jul 28;11:243. PMID: 22839209</ref> These mutations cause decreased binding affinities of inhibitors, a huge factor being steric clashing. For pyrimethamine and cycloguanil specifically, the N51I mutation greatly effects their ability to bind the enzyme due to the drugs' rigid chlorophenyl substituents. In an effort to mitigate the effect of the mutations, the commonly occurring quadruple mutant must be addressed in the research of new PfDHFR targeting drugs. |
| - | A first step in this direction was to experiment with the drug <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Wr99210/1'>WR99210</scene> that, with its (2,4,5-trichlorophenoxy)propoxy side chain, addressed the steric clash that <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Pyrimethamine_with_wt_pfdhfr/2'>pyrimethamine</scene> was subjected to with a S108N mutation. However further research with this drug was stopped because of its gastrointestinal toxicity in humans and low bioavailbility. Wr99210 was significantly more basic than pyrimethamine, a pyrimidine and slightly acidic substance to match that of the gastrointestinal track, and thus was not readily absorbed in the intestines. Though it was effective at getting deep into the mutant PfDHFR active site, its ineffectiveness as an oral drug would have made it unsuccessful. | + | A first step in this direction was to experiment with the drug <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Wr99210/1'>WR99210</scene> that, with its (2,4,5-trichlorophenoxy)propoxy side chain, addressed the steric clash that <scene name='Malarial_Dihydrofolate_Reductase_as_Drug_Target/Pyrimethamine_with_wt_pfdhfr/2'>pyrimethamine</scene> was subjected to with a S108N mutation. However further research with this drug was stopped because of its gastrointestinal toxicity in humans and low bioavailbility.<ref>Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16823-8. Epub 2012 Oct 3. PMID:23035243. doi: 10.1073/pnas.1204556109.</ref> Wr99210 was significantly more basic than pyrimethamine, a pyrimidine and slightly acidic substance to match that of the gastrointestinal track, and thus was not readily absorbed in the intestines. Though it was effective at getting deep into the mutant PfDHFR active site, its ineffectiveness as an oral drug would have made it unsuccessful. |
It was resolved that a 2,4-diaminopyrimidine anchor on a new drug would allow the steric hindrance found with pyrimethamine to be avoided by replacing its rigid chlorophenyl group. In addition to this anchor allowing deep binding into the active site of PfDHFR, the other end of the molecule, an alpha-carboxylate, would form strong hydrogen bonds with the conserved Arg122. | It was resolved that a 2,4-diaminopyrimidine anchor on a new drug would allow the steric hindrance found with pyrimethamine to be avoided by replacing its rigid chlorophenyl group. In addition to this anchor allowing deep binding into the active site of PfDHFR, the other end of the molecule, an alpha-carboxylate, would form strong hydrogen bonds with the conserved Arg122. | ||
| Line 17: | Line 17: | ||
Species Specificity | Species Specificity | ||
---- | ---- | ||
| - | + | There are three regions of the DHFR active site that differ between human and ''Plasmodium falciparum'' that allows a drug to target the PfDHFR specifically while not harming that of humans. | |
</StructureSection> | </StructureSection> | ||
| + | |||
| + | |||
Revision as of 07:23, 29 November 2012
Introduction
There are currently antimalarial drugs that target the malarial dihydrofolate reductase (DHFR) such as pyrimethamine and cycloguanil. However, the effectiveness of these drugs has decreased because of mutations in the enzyme that have led to drug resistance. New research in drug development now incorporates both the wild-type as well as the quadruple mutant DHFR from the Plasmodium falciparum malarial strain.
| |||||||||||
References
- ↑ Huang F, Tang L, Yang H, Zhou S, Liu H, Li J, Guo S. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J. 2012 Jul 28;11:243. PMID: 22839209
- ↑ Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16823-8. Epub 2012 Oct 3. PMID:23035243. doi: 10.1073/pnas.1204556109.
Proteopedia Page Contributors and Editors (what is this?)
Mary Smith, Alexander Berchansky, Karsten Theis, Michal Harel
